Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 19/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16600400 | 0.99 | ENPP2 (0.61) | ENPP2KDM4EMEN1POLBMAPT | |
| SCHEMBL16600398 | 0.93 | ENPP2 (0.62) | ENPP2MEN1KMT2A | |
| SCHEMBL16600382 | 0.91 | ENPP2 (0.53) | ENPP2MAPT | |
| SCHEMBL17943014 | 0.89 | ENPP2 (0.61) | ENPP2KDM4EMEN1POLBMAPT | |
| SCHEMBL16600463 | 0.88 | ENPP2 (0.61) | ENPP2KDM4EMEN1POLBMAPT | |
| SCHEMBL19750145 | 0.86 | ENPP2 (0.64) | ENPP2 | |
| SCHEMBL16614270 | 0.85 | ENPP2 (0.78) | ENPP2 | |
| SCHEMBL16600499 | 0.84 | ENPP2 (0.77) | ENPP2 | |
| SCHEMBL16600461 | 0.82 | ENPP2 (0.54) | ENPP2KDM4EMEN1POLBMAPT | |
| SCHEMBL16600615 | 0.82 | ENPP2 (0.73) | ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9850203-B2 | Autotaxin inhibitor compounds | PHARMAKEA, INC. (US) | 2017-12-26 | — | — | US | claimed |
| EP-3049405-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | Pharmakea Inc. (US) | 2016-08-03 | — | — | EP | claimed |
| US-20160214935-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | DF 2024 IP ACQUISITION, LLC | 2016-07-28 | — | — | US | claimed |
| WO-2015048301-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | PHARMAKEA, INC. (US) | 2015-04-02 | — | — | WO | claimed |
| US-9850203-B2 | Autotaxin inhibitor compounds | PHARMAKEA, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-9850203-B2 | Autotaxin inhibitor compounds | PHARMAKEA, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-9850203-B2 | Autotaxin inhibitor compounds | PHARMAKEA, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| EP-3049405-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | Pharmakea Inc. (US) | 2016-08-03 | — | — | EP | disclosed |
| US-20160214935-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | DF 2024 IP ACQUISITION, LLC | 2016-07-28 | — | — | US | disclosed |
| US-20160214935-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | DF 2024 IP ACQUISITION, LLC | 2016-07-28 | — | — | US | disclosed |
| US-20160214935-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | DF 2024 IP ACQUISITION, LLC | 2016-07-28 | — | — | US | disclosed |
| WO-2015048301-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | PHARMAKEA, INC. (US) | 2015-04-02 | — | — | WO | disclosed |
| WO-2015048301-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | PHARMAKEA, INC. (US) | 2015-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160214935-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | ENPP2, SERPINB1, SERPINE1 | ENPP2 1/4885KDM4E 4044/4885MEN1 737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.